According to the US Food and Drug Administration (FDA), new guidance from the regulator could save biosimilar developers up to 50% of their pharmacokinetic (PK) study costs, or approximately $20m.
As part of an effort to lower drug costs, the FDA has made an announcement to facilitate the development of proposed
Register for free to keep reading
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day